Biogen, Sangamo Team To Cure Sickle Cell Disease, Beta-Thalassemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen paid $20 million upfront to Sangamo in a deal to co-develop autologous stem cell treatments for the two hemoglobinopathies. Sangamo retains an option to co-promote both indications in the U.S. and could earn $300 million in milestones, plus sales royalties.